Abstract:Abstract Background Acral melanoma (AM) is the most common subtype in Chinese melanoma patients with a very poor prognosis. However, our understanding of the disease pathogenesis and molecular landscape is limited by the few studies that have been conducted. Here, we profiled the clinical characteristics, mutational landscapes and tumor immune microenvironment of AM patients to gain insights into disease characteristics and potential treatment strategies. Methods A total of 90 AM patients were enrolled and their tissue samples were subjected to next-generation sequencing and multiplexed immunohistochemistry tests. Kaplan–Meier curves and log-rank tests were used to analyze the prognostic potential of various genetic aberrations and immune cell compositions in AM. Results The median disease-free survival was 21.3 months and estimated median overall survival (OS) was 60 months. More advanced stages, older ages and thickness of greater than 4 mm were associated with worse prognosis in AM patients (HR = 2.57, 95% CI 1.25–5.29, p = 0.01; HR = 2.77, 95% CI 1.22–6.28, p = 0.02; HR = 3.43, 95% CI 1.51–7.82, p < 0.01, respectively), while patients who received post-surgical treatments had better survival (HR = 0.36, 95% CI 0.17–0.76, p = 0.01). The most frequently altered genes included BRAF (14.5%), KIT (16.9%), NRAS (12%), NF1 (10.8%), APC (7.2%), and ARID2 (6%). Copy number variations (CNV) were commonly found in CCND1 (19.3%), CDK4 (19.3%), MDM2 (14.5%) and FGF19 (12%). CDK4 amplifications was independently associated with shorter OS in AM patients (HR = 3.61, 95% CI 1.38–9.46, p = 0.01). CD8 + T cells (p < 0.001) and M1 macrophages (p = 0.05) were more highly enriched in the invasive margin than in the tumor center. Patients with higher levels of M1 macrophage infiltration in the invasive margin derived markedly longer OS (HR = 0.43, 95% CI 0.20–0.95, p = 0.03). Interestingly, in CDK4-amplified patients, there tended to be a low level of M1 macrophage infiltration in the invasive margin (p = 0.06), which likely explains the poor prognosis in such patients. Conclusions Our study provided a comprehensive portrait of the clinicopathological features, genetic aberrations and tumor microenvironment profiles in AM patients and identified candidate prognostic factors, which may facilitate development of additional therapeutic options and better inform clinical management of AM patients. Based on these prognostic factors, further studies should focus on enhancing the infiltration of M1 macrophages, especially in CDK4-amplified AM patients.

A Mutational Survey of Acral Nevi

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi

Whole Genome and RNA Sequencing Reveal the Distinct Genomic Landscape of Acral Melanoma.

Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations

The genetic evolution of acral melanoma

1173P NRAS Mutation As an Independent Prognostic Factor for Resectable Chinese Acral Melanoma

Prognostic Value of Genetic Aberrations and Tumor Immune Microenvironment in Primary Acral Melanoma

Mutational Profiling of Melanomas in Patients from the Southeast Coast of China.

Ancestry and somatic profile predict acral melanoma origin and prognosis

Comprehensive Genomic Profiling Reveals Distinct Patterns of Driver Mutations and Chromosomal Alterations in Acral and Mucosal Melanomas.

Analysis of BRAF Gene Mutation of Melanoma Derived from Different Sources

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Nevus-associated Acral Melanoma Has Lower Risk of Recurrence and Mortality Than De Novo Acral Melanoma: A Multicenter, Retrospective Analysis of 482 Patients

Whole-genome landscapes of major melanoma subtypes

Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma

Prevalence of BRAF V600E Mutation in Chinese Melanoma Patients: Large Scale Analysis of BRAF and NRAS Mutations in a 432-Case Cohort.

Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma

A single-cell atlas reveals tumor heterogeneity and immune environment of acral melanoma

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center